Back to search

Boston University

Defining the impact of blood cell clycan expression on blood components

Abstract

dc:description.abstract

Background: ABO(H)blood group antigens are expressed on red blood cells (RBCs) and platelets. ABO(H)-incompatible RBC transfusion poses a significant risk for hemolytic transfusion reactions, although in vivo hemolysis can be variable. ABO(H)-incompatible platelet transfusion is generally considered safe; however, post-transfusion count increments can vary. Differences in ABO(H) glycan expression on transfused RBCs/PLTs may influence interactions with recipient anti-A/B antibodies and therefore affect clinical outcomes. Objective: Determine whether ABO glycan expression on platelets correlates with red blood cell expression within individual donors by quantitatively measuring antigen expression using flow cytometry. Methods: Residual blood samples from healthy donors were collected RBCs and platelets isolated by centrifugation. ABH glycan expression was quantified by flow cytometry using anti-A or anti-B antibodies with anti-mouse IgM as the secondary antibody. Median fluorescence intensity (MFI) value was obtained for RBCs and platelets from each individual donor for analysis. Primary antibody concentration was optimized prior to measuring ABH glycan expression on a healthy donor cohort. Statistical analysis (descriptive statistics, coefficient of variation (CV), normality testing, frequency distribution, and Spearman’s rank correlation) was performed using GraphPad Prism. Results: The optimal antibody concentration for maximizing detection of ABO glycans on RBCs while avoiding agglutination was 1:200. Undiluted antibody achieved the best optimal median fluorescence intensity for platelets. ABH glycan expression remained stable through 28 days for RBCs, comparing day 7 vs day 14. ABH glycan expression in platelets only remained stable through 14 days, when comparing day 7 vs day 14. ABH glycan expression in RBCs approximated a Gaussian distribution across individuals, whereas platelet ABH glycan expression demonstrated greater heterogeneity. There was poor/moderate correlation ABH expression between RBCs and PLTs. Individuals with distinct patterns of high/low median fluorescence intensity were observed on platelets compared to a more consistent median fluorescence intensity on RBCs. Conclusions: ABO glycan expression on RBCs and platelets vary widely across individuals with poor correlation between RBCs and platelets within individuals. These findings suggest that ABO(H) glycan expression is regulated by distinct processes in RBCs and PLTs that may influence outcomes following major ABO(H)-incompatible transfusion.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Medical Sciences
Grantor
Boston University
Year dc:date.issued
2026

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Yean, Aaron
Advisors dc:contributor.advisor
  • Herscovitz, Haya
  • Stowell, Sean R.

Subjects

dc:subject × 1

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/53798

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Yean, Aaron. Defining the impact of blood cell clycan expression on blood components. masters thesis, Boston University, 2026. https://hdl.handle.net/2144/53798